Screener
AbCellera Biologics Inc. ABCL Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
FAQ
- What is AbCellera Biologics Inc.'s equity securities without readily determinable fair value impairment loss annual amount?
- AbCellera Biologics Inc. (ABCL) reported equity securities without readily determinable fair value impairment loss annual amount of $6.1M in Q2 2026.
- What does equity securities without readily determinable fair value impairment loss annual amount mean?
- Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount as reported by AbCellera Biologics Inc. Common Shares.
Ask your AI about AbCellera Biologics Inc.'s equity securities without readily determinable fair value impairment loss annual amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude